Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16547507 | 0.77 | CYP2C9 (0.52) | CYP2C9CYP2C19CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL27596757 | 0.73 | LTA4H (0.35) | LTA4H | |
| SCHEMBL2013381 | 0.73 | LTA4H (0.35) | LTA4H | |
| SCHEMBL276722 | 0.73 | LTA4H (0.35) | LTA4H | |
| SCHEMBL27606838 | 0.73 | LTA4H (0.35) | LTA4H | |
| SCHEMBL1715132 | 0.72 | CYP2E1 (0.45) | CYP2C9CYP2C19CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL26155647 | 0.72 | LTA4H (0.33) | LTA4H | |
| SCHEMBL9798925 | 0.71 | LTA4H (0.34) | LTA4H | |
| SCHEMBL213934 | 0.70 | CYP2C9 (0.37) | CYP2C9CYP2C19CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL26098599 | 0.70 | CYP2C9 (0.41) | CYP2C9CYP2C19CYP2E1CYP2A6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388886-A1 | Cas12a Endonuclease Variants and Methods of Use | ENSOMA APS (DK) | 2025-12-25 | — | — | US | claimed |
| EP-4460566-A2 | CAS12A ENDONUCLEASE VARIANTS AND METHODS OF USE | Ensoma ApS (DK) | 2024-11-13 | — | — | EP | claimed |
| CN-118742641-A | CAS12A endonuclease variants and methods of use | 安索玛私人有限责任公司 | 2024-10-01 | — | — | CN | claimed |
| WO-2024149841-A1 | DETECTION OF MODIFIED NUCLEOBASES IN DNA SAMPLES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-07-18 | — | — | WO | claimed |
| WO-2024083982-A1 | DETECTION OF MODIFIED NUCLEOBASES IN NUCLEIC ACID SAMPLES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-04-25 | — | — | WO | claimed |
| CN-117659207-A | Double-base editing system and application thereof | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | 2024-03-08 | — | — | CN | claimed |
| WO-2024047552-A1 | SYSTEMS AND METHODS FOR TARGETED GENOME-EDITING IN PLANTS | INDIAN COUNCIL OF AGRICULTURAL RESEARCH (IN) | 2024-03-07 | — | — | WO | claimed |
| WO-2023217280-A1 | PROGRAMMABLE ADENINE BASE EDITOR AND USES THEREOF | HUIDAGENE THERAPEUTICS CO., LTD. (CN) | 2023-11-16 | — | — | WO | claimed |
| WO-2023131870-A2 | ENDONUCLEASE VARIANTS AND METHODS OF USE | TWELVE BIO APS (DK) | 2023-07-13 | — | — | WO | claimed |
| EP-4014046-A1 | DNA REPAIR BLOOD TEST FOR PREDICTING RESPONSE OF LUNG CANCER PATIENTS TO IMMUNOTHERAPY | Yeda Research and Development Co. Ltd (IL) | 2022-06-22 | — | — | EP | claimed |
| EP-1579015-A4 | METHOD FOR PCR CLEANUP AND OLIGONUCLEOTIDE REMOVAL | APPLERA CORP (US) | 2006-06-21 | — | — | EP | claimed |
| EP-1579015-A2 | METHOD FOR PCR CLEANUP AND OLIGONUCLEOTIDE REMOVAL | Applera Corporation (US) | 2005-09-28 | — | — | EP | claimed |
| EP-1579015-A3 | METHOD FOR PCR CLEANUP AND OLIGONUCLEOTIDE REMOVAL | Applera Corporation (US) | 2005-08-25 | — | — | EP | claimed |
| US-20040023220-A1 | Integrated method for PCR cleanup and oligonucleotide removal | APPLIED BIOSYSTEMS, LLC | 2004-02-05 | — | — | US | claimed |
| WO-2004009851-A2 | METHOD FOR PCR CLEANUP AND OLIGONUCLEOTIDE REMOVAL | APPLERA CORPORATION (US) | 2004-01-29 | — | — | WO | claimed |
| EP-1337668-A2 | METHOD FOR DETECTING METHYLATION STATES FOR A TOXICOLOGICAL DIAGNOSTIC | Epigenomics AG (DE) | 2003-08-27 | — | — | EP | claimed |
| WO-2002040710-A2 | METHOD FOR DETECTING METHYLATION STATES FOR A TOXICOLOGICAL DIAGNOSTIC | EPIGENOMICS AG (DE) | 2002-05-23 | — | — | WO | claimed |
| EP-0934521-A1 | IN VITRO ASSAY FOR CARCINOGENS USING PHENOTYPIC TRANSFORMATION OF HUMAN CELLS | Viratest Carcinogen Monitoring, Ltd. (CA) | 1999-08-11 | — | — | EP | claimed |
| US-5763180-A | In vitro assay for carcinogens using phenotypic transformation of human cells | VIRATEST CARCINOGEN MONITORING LTD. (CA) | 1998-06-09 | — | — | US | claimed |
| WO-1998007030-A1 | IN VITRO ASSAY FOR CARCINOGENS USING PHENOTYPIC TRANSFORMATION OF HUMAN CELLS | VIRATEST CARCINOGEN MONITORING LTD. (US) | 1998-02-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388886-A1 | Cas12a Endonuclease Variants and Methods of Use | CDA, MUS81, DNASE1L3 | CYP2C9 2979/4885CYP2C19 4345/4885CYP2E1 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.